Alcon announces new CEO

Article

As of March 31st this year, Cary Rayment will retire as president and chief executive officer of Alcon, Inc; he will be replaced on April 1st by Kevin Buehler.

As of March 31st this year, Cary Rayment will retire as president and chief executive officer of Alcon, Inc; he will be replaced on April 1st by Kevin Buehler, currently senior vice president, global markets and chief marketing officer of Alcon's subsidiary, Alcon Laboratories, Inc. Mr Rayment will continue in his role as director and non-executive chairman of the board, and Mr Buehler will be nominated for board membership at Alcon's annual general meeting on May 5th.

Mr Buehler, who is responsible for the Surgical, Pharmaceutical and Consumer groups, joined Alcon as a regional sales manager in 1984. In the last 24 years, he has held various positions within the company, including vice president of Alcon's Managed Care and Falcon Generic Pharmaceuticals group and area vice president in the International Division for Latin America, Canada, Australia and the Far East.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.